Other Neuropsychiatric Disorders & General Information

 (Haga un click en la información del journal para acceder al resúmen)

5 – doble-ciego o metanálisis; 4 – subanálisis o simple ciego; 3 – revisión, abierto, básico; 2 – casos; 1 – opinión

 

3 - Medication Adherence: A Review of the Literature and Implications for Clinical Practice

Julius, Rose J; Novitsky, Mark A. Jr; Dubin, William R

Journal of Psychiatric Practice:Volume 15(1)January 2009pp 34-44

 

3! - Risks and Predictors of Readmission for a Mental Disorder During the Postpartum Period

Trine Munk-Olsen, Thomas Munk Laursen, Tamar Mendelson, Carsten B. Pedersen, Ole Mors, Preben Bo Mortensen

Arch Gen Psychiatry. 2009;66(2):189-195

 

GRATIS 3 - Borderline and antisocial personality disorders: summary of NICE guidance

Tim Kendall, Stephen Pilling, Peter Tyrer, Conor Duggan, Rachel Burbeck, Nicholas Meader, Clare Taylor

BMJ 2009;338:b93

 

3 - Phospholipase A₂ activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease

Original Investigation

Phospholipase A₂ activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease

Evelin L. Schaeffer, Orestes V. Forlenza and Wagner F. Gattaz

Psychopharmacology. Volume 202, Numbers 1-3 / Jan 2009: 37-51

 

3 - Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine

Original Investigation

Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine

Serena Deiana, Charles R. Harrington, Claude M. Wischik and Gernot Riedel

Psychopharmacology. Volume 202, Numbers 1-3 / Jan 2009: 53-65

 

3 - Galantamine-induced improvements in cognitive function are not related to alterations in α₄β₂ nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[¹⁸F]Fluoro-A-85380 PET

Original Investigation

Galantamine-induced improvements in cognitive function are not related to alterations in α₄β₂ nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[¹⁸F]Fluoro-A-85380 PET

J. R. Ellis, P. J. Nathan, V. L. Villemagne, R. S. Mulligan, T. Saunder, K. Young, C. L. Smith, J. Welch, M. Woodward, K. A. Wesnes, G. Savage and C. C. Rowe

Psychopharmacology. Volume 202, Numbers 1-3 / Jan 2009: 79-91

 

3 - MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a “brain tonic”

Original Investigation

MK801- and scopolamine-induced amnesias are reversed by an Amazonian herbal locally used as a “brain tonic”

Adriana Lourenço da Silva, Bárbara da Silva Martins, Viviane de Moura Linck, Ana Paula Herrmann, Nathalia Mai, Domingos S. Nunes and Elaine Elisabetsky

Psychopharmacology. Volume 202, Numbers 1-3 / Jan 2009: 165-172

 

GRATIS 3! - Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

Review

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement

Olga A. H. Reneerkens, Kris Rutten, Harry W. M. Steinbusch, Arjan Blokland and Jos Prickaerts

Psychopharmacology. Volume 202, Numbers 1-3 / January, 2009: 419-443

 

GRATIS 3! - Dementia

Alistair Burns, Steve Iliffe

BMJ 2009;338:b75

 

GRATIS 3! - Alzheimer’s disease

Alistair Burns, Steve Iliffe

BMJ 2009;338:b158

 

4 - Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials

References and further reading may be available for this article. To view references and further reading you must purchase this article.

Shantha MW Rajaratnam, Mihael H Polymeropoulos, Dennis M Fisher, Thomas Roth, Christin Scott, Gunther Birznieks and Dr Elizabeth B Klerman

The Lancet. Volume 373, Issue 9662, 7 February 2009-13 February 2009, Pages 482-491

 

3 - Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease

Gwenn S. Smith, Elisse Kramer, Yilong Ma, Carol R. Hermann, Vijay Dhawan, Thomas Chaly and David Eidelberg

Brain 2009 132(2):392-401

 

GRATIS 3 - Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer's Disease
George T. Grossberg, Vojislav Pejovic, Michael L. Miller, Stephen M. Graham
Dement Geriatr Cogn Disord 2009;27:164-172

 

GRATIS 3 - Epidemiology of Anorexia Nervosa in Men: A Nationwide Study of Finnish Twins

Raevuori A, Hoek HW, Susser E, Kaprio J, Rissanen A, et al.

PLoS ONE 2009; 4(2): e4402

 

5< - A Double-Blind, Randomized, Placebo-Controlled Trial of Paroxetine Controlled-Release in Irritable Bowel Syndrome

Prakash S. Masand, Chi-Un Pae, Stan Krulewicz, Kathleen Peindl, Paolo Mannelli, Indu M. Varia, and Ashwin A. Patkar

Psychosomatics 2009; 50:78-86, January-February

3! - Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease

Venneri, Annalena; Lane, Roger

NeuroReport:Volume 20(3)18 February 2009pp 285-288

 

3 - Inactivation of cholinesterase induced by non-steroidal anti-inflammatory drugs with horseradish peroxidase: Implication for Alzheimer's disease

References and further reading may be available for this article. To view references and further reading you must purchase this article.

Sanae Muraoka and Toshiaki Miura

Life Sciences. Volume 84, Issues 9-10, 27 February 2009, Pages 272-277

 

3 - Safety of therapeutic methylphenidate in adults: a systematic review of the evidence

J Godfrey

Journal of Psychopharmacology, Vol. 23, No. 2, 194-205 (2009)

5< - Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study

Ruth Remington, Amy Chan, James Paskavitz, Thomas B. Shea

American Journal of Alzheimer's Disease and Other Dementias, Vol. 24, No. 1, 27-33 (2009)

3 - Newer treatments for fibromyalgia syndrome

Richard E Harris, Daniel J Clauw

Therapeutics and Clinical Risk Management. December 2008; Issue 6

 

3! - Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD

Lenard A. Adler, Thomas Spencer, James J. McGough, Hai Jiang, Rafael Muniz

Journal of Attention Disorders, Vol. 12, No. 5, 449-459 (2009)

3 - Delirium in the intensive care unit

Alessandro Morandi;  James C. Jackson; E. Wesley Ely

International Review of Psychiatry, Volume 21, Issue 1 February 2009, pages 43 - 58

 

3 - Delirium and long-term cognitive impairment

Alasdair M. J. MacLullich;  Anna Beaglehole;  Roanna J. Hall; David J. Meagher

International Review of Psychiatry, Volume 21, Issue 1 February 2009, pages 30 - 42

 

3 - Cannabidiol: A Promising Drug for Neurodegenerative Disorders?

Teresa Iuvone, Giuseppe Esposito, Daniele De Filippis, Caterina Scuderi & Luca Steardo

CNS Neuroscience & Therapeutics. Volume 15 Issue 1, Pages 65 - 75

 

3 - Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia

Gary Richardson, Sherry Wang-Weiga

Human Psychopharmacology: Clinical and Experimental. Volume 24 Issue 2, Pages 103 - 111

 

3! - Mentally Stimulating Activities at Work During Midlife and Dementia Risk After Age 75: Follow-Up Study From the Kungsholmen Project

Karp, Anita; Andel, Ross; Parker, Marti G.; Wang, Hui-Xin; Winblad, Bengt; Fratiglioni, Laura

American Journal of Geriatric Psychiatry: March 2009 - Volume 17 - Issue 3 - pp 227-236

 

3 - Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?

J K Foster, G Verdile, K A Bates and R N Martins

Molecular Psychiatry (2009) 14, 239–251

 

3! - Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes

Yeong-Liang Lin, Mei-Fen Kung

Pharmacoepidemiology and Drug Safety 2009; Volume 18 Issue 3, Pages 235 - 239

 

3 - The Modulation of Synaptic GABA_A Receptors in the Thalamus by Eszopiclone and Zolpidem

Fan Jia, Peter A. Goldstein, and Neil L. Harrison

JPET 328:1000-1006, 2009

 

5 - A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia

Katsuyoshi Mizukami, Takashi Asada, Toru Kinoshita, Katsuaki Tanaka, Kazuki Sonohara, Ryuhei Nakai, Kiyoshi Yamaguchi, Haruo Hanyu, Kiyoshi Kanaya, Tetsuya Takao, Masakatsu Okada, Sumio Kudo, Hayato Kotoku, Masahiko Iwakiri, Hirofumi Kurita, Toshihiro Miyamura, Yosuke Kawasaki, Koji Omori, Kazumasa Shiozaki, Toshinari Odawara, Tatsuya Suzuki, Shizuru Yamada, Youichi Nakamura and Kenji Toba

The International Journal of Neuropsychopharmacology (2009), 12:191-199

 

3 - Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease

References and further reading may be available for this article. To view references and further reading you must purchase this article.

Katsuyoshi Mizukami, Kimitaka Hatanaka, Yoshiro Tanaka, Shinji Sato and Takashi Asada

Progress in Neuro-Psychopharmacology and Biological Psychiatry. Volume 33, Issue 2, 17 March 2009, Pages 349-352

 

3 - Factors associated with choice of psychotropic drugs used for intentional drug overdose

ORIGINAL PAPER

Factors associated with choice of psychotropic drugs used for intentional drug overdose

Marie Tournier, Adeline Grolleau, Audrey Cougnard, Mathieu Molimard and Hélène Verdoux

European Archives of Psychiatry and Clinical Neuroscience. Volume 259, Number 2 / February, 2009: 86-91

 

5 - A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

ORIGINAL PAPER

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

Michael Rösler, Roland Fischer, Richard Ammer, Claudia Ose, Wolfgang Retz and on behalf of the study group

European Archives of Psychiatry and Clinical Neuroscience. Volume 259, Number 2 / February, 2009: 120-129

 

GRATIS 3! - FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. Agency warns against chronic use of these products to treat gastrointestinal disorders

FDA NEWS. Feb. 26, 2009

 

GRATIS 3! - Tratamiento con fármacos anticomiciales de los trastornos de la personalidad 
M. Díaz-Marsá, K. Tajima, A. Montes, J. L. Carrasco

Actas Esp Psiquiatr 2008;36(Suppl. 3):39-45

 

GRATIS 3! - Anticonvulsivantes en la terapéutica de la impulsividad 
S. Ros Montalbán, B. Díez Múgica, N. Casanova Alba

Actas Esp Psiquiatr 2008;36(Suppl. 3):46-62

 

GRATIS 3 - Neuropsychiatric Masquerades

Arline Kaplan

Psychiatric Times. Feb 2009; Vol. 26 No. 2

.

Regresar a RESÚMENES FEBRERO 2009